Home health remedies Roche under fire again: Mylan launches Herceptin copycat in latest blow to...

Roche under fire again: Mylan launches Herceptin copycat in latest blow to blockbuster trio

9
0
SHARE

Much has been made of the challenges Roche’s blockbuster oncology troika faces with U.S. biosimilars hitting the market in quick succession. So far, those challengers haven’t made much of a dent in Roche’s sales stateside––but a new contestant could help tip the scales.

Mylan and Biocon have launched their Herceptin copy, Ogivri, in the U.S., making it the second biosim on the market for Roche’s blockbuster breast and stomach cancer drug. 

Mylan said in a release that Ogivri would hit the market at a “competitive discount” to Herceptin but did not disclose the list price for its 420-milligram and 150-milligram vials. 

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

“With regulatory approval for our biosimilar (Herceptin) in more than 80 countries worldwide, we are bringing vast global biosimilars experience to the U.S. and look forward to continuing our work with all stakeholders in the healthcare system to reduce costs, improve access and advance care,” Mylan President Rajiv Malik said in a statement. 

RELATED: Say hello to Roche’s worst-case scenario: Teva’s Rituxan biosim set to launch in U.S.

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here